Global KRAS Inhibitor Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
According to our (Global Info Research) latest study, the global KRAS Inhibitor market size was valued at US$ 138 million in 2024 and is forecast to a readjusted size of USD 237 million by 2031 with a CAGR of 8.1% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
This report is a detailed and comprehensive analysis for global KRAS Inhibitor market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global KRAS Inhibitor market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global KRAS Inhibitor market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global KRAS Inhibitor market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global KRAS Inhibitor market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for KRAS Inhibitor
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global KRAS Inhibitor market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, Incyte, Mirati Therapeutics, Novartis, Jemincare, Cardiff Oncology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
KRAS Inhibitor market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe KRAS Inhibitor product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of KRAS Inhibitor, with price, sales quantity, revenue, and global market share of KRAS Inhibitor from 2020 to 2025.
Chapter 3, the KRAS Inhibitor competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the KRAS Inhibitor breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and KRAS Inhibitor market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of KRAS Inhibitor.
Chapter 14 and 15, to describe KRAS Inhibitor sales channel, distributors, customers, research findings and conclusion.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
This report is a detailed and comprehensive analysis for global KRAS Inhibitor market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global KRAS Inhibitor market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global KRAS Inhibitor market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global KRAS Inhibitor market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global KRAS Inhibitor market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for KRAS Inhibitor
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global KRAS Inhibitor market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, Incyte, Mirati Therapeutics, Novartis, Jemincare, Cardiff Oncology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
KRAS Inhibitor market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Others
- Clinic Laboratories
- Cancer Diagnostic Centres
- Hospitals
- Others
- Amgen
- Boehringer Ingelheim
- BridgeBio Pharma
- Erasca
- Innovent Biologics
- Incyte
- Mirati Therapeutics
- Novartis
- Jemincare
- Cardiff Oncology
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe KRAS Inhibitor product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of KRAS Inhibitor, with price, sales quantity, revenue, and global market share of KRAS Inhibitor from 2020 to 2025.
Chapter 3, the KRAS Inhibitor competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the KRAS Inhibitor breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and KRAS Inhibitor market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of KRAS Inhibitor.
Chapter 14 and 15, to describe KRAS Inhibitor sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global KRAS Inhibitor Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Lung Cancer
1.3.3 Pancreatic Cancer
1.3.4 Colorectal Cancer
1.3.5 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global KRAS Inhibitor Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Clinic Laboratories
1.4.3 Cancer Diagnostic Centres
1.4.4 Hospitals
1.4.5 Others
1.5 Global KRAS Inhibitor Market Size & Forecast
1.5.1 Global KRAS Inhibitor Consumption Value (2020 & 2024 & 2031)
1.5.2 Global KRAS Inhibitor Sales Quantity (2020-2031)
1.5.3 Global KRAS Inhibitor Average Price (2020-2031)
2 MANUFACTURERS PROFILES
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen KRAS Inhibitor Product and Services
2.1.4 Amgen KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Amgen Recent Developments/Updates
2.2 Boehringer Ingelheim
2.2.1 Boehringer Ingelheim Details
2.2.2 Boehringer Ingelheim Major Business
2.2.3 Boehringer Ingelheim KRAS Inhibitor Product and Services
2.2.4 Boehringer Ingelheim KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Boehringer Ingelheim Recent Developments/Updates
2.3 BridgeBio Pharma
2.3.1 BridgeBio Pharma Details
2.3.2 BridgeBio Pharma Major Business
2.3.3 BridgeBio Pharma KRAS Inhibitor Product and Services
2.3.4 BridgeBio Pharma KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 BridgeBio Pharma Recent Developments/Updates
2.4 Erasca
2.4.1 Erasca Details
2.4.2 Erasca Major Business
2.4.3 Erasca KRAS Inhibitor Product and Services
2.4.4 Erasca KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Erasca Recent Developments/Updates
2.5 Innovent Biologics
2.5.1 Innovent Biologics Details
2.5.2 Innovent Biologics Major Business
2.5.3 Innovent Biologics KRAS Inhibitor Product and Services
2.5.4 Innovent Biologics KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Innovent Biologics Recent Developments/Updates
2.6 Incyte
2.6.1 Incyte Details
2.6.2 Incyte Major Business
2.6.3 Incyte KRAS Inhibitor Product and Services
2.6.4 Incyte KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Incyte Recent Developments/Updates
2.7 Mirati Therapeutics
2.7.1 Mirati Therapeutics Details
2.7.2 Mirati Therapeutics Major Business
2.7.3 Mirati Therapeutics KRAS Inhibitor Product and Services
2.7.4 Mirati Therapeutics KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Mirati Therapeutics Recent Developments/Updates
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis KRAS Inhibitor Product and Services
2.8.4 Novartis KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Novartis Recent Developments/Updates
2.9 Jemincare
2.9.1 Jemincare Details
2.9.2 Jemincare Major Business
2.9.3 Jemincare KRAS Inhibitor Product and Services
2.9.4 Jemincare KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Jemincare Recent Developments/Updates
2.10 Cardiff Oncology
2.10.1 Cardiff Oncology Details
2.10.2 Cardiff Oncology Major Business
2.10.3 Cardiff Oncology KRAS Inhibitor Product and Services
2.10.4 Cardiff Oncology KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Cardiff Oncology Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: KRAS INHIBITOR BY MANUFACTURER
3.1 Global KRAS Inhibitor Sales Quantity by Manufacturer (2020-2025)
3.2 Global KRAS Inhibitor Revenue by Manufacturer (2020-2025)
3.3 Global KRAS Inhibitor Average Price by Manufacturer (2020-2025)
3.4 Market Share Analysis (2024)
3.4.1 Producer Shipments of KRAS Inhibitor by Manufacturer Revenue ($MM) and Market Share (%): 2024
3.4.2 Top 3 KRAS Inhibitor Manufacturer Market Share in 2024
3.4.3 Top 6 KRAS Inhibitor Manufacturer Market Share in 2024
3.5 KRAS Inhibitor Market: Overall Company Footprint Analysis
3.5.1 KRAS Inhibitor Market: Region Footprint
3.5.2 KRAS Inhibitor Market: Company Product Type Footprint
3.5.3 KRAS Inhibitor Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global KRAS Inhibitor Market Size by Region
4.1.1 Global KRAS Inhibitor Sales Quantity by Region (2020-2031)
4.1.2 Global KRAS Inhibitor Consumption Value by Region (2020-2031)
4.1.3 Global KRAS Inhibitor Average Price by Region (2020-2031)
4.2 North America KRAS Inhibitor Consumption Value (2020-2031)
4.3 Europe KRAS Inhibitor Consumption Value (2020-2031)
4.4 Asia-Pacific KRAS Inhibitor Consumption Value (2020-2031)
4.5 South America KRAS Inhibitor Consumption Value (2020-2031)
4.6 Middle East & Africa KRAS Inhibitor Consumption Value (2020-2031)
5 MARKET SEGMENT BY TYPE
5.1 Global KRAS Inhibitor Sales Quantity by Type (2020-2031)
5.2 Global KRAS Inhibitor Consumption Value by Type (2020-2031)
5.3 Global KRAS Inhibitor Average Price by Type (2020-2031)
6 MARKET SEGMENT BY APPLICATION
6.1 Global KRAS Inhibitor Sales Quantity by Application (2020-2031)
6.2 Global KRAS Inhibitor Consumption Value by Application (2020-2031)
6.3 Global KRAS Inhibitor Average Price by Application (2020-2031)
7 NORTH AMERICA
7.1 North America KRAS Inhibitor Sales Quantity by Type (2020-2031)
7.2 North America KRAS Inhibitor Sales Quantity by Application (2020-2031)
7.3 North America KRAS Inhibitor Market Size by Country
7.3.1 North America KRAS Inhibitor Sales Quantity by Country (2020-2031)
7.3.2 North America KRAS Inhibitor Consumption Value by Country (2020-2031)
7.3.3 United States Market Size and Forecast (2020-2031)
7.3.4 Canada Market Size and Forecast (2020-2031)
7.3.5 Mexico Market Size and Forecast (2020-2031)
8 EUROPE
8.1 Europe KRAS Inhibitor Sales Quantity by Type (2020-2031)
8.2 Europe KRAS Inhibitor Sales Quantity by Application (2020-2031)
8.3 Europe KRAS Inhibitor Market Size by Country
8.3.1 Europe KRAS Inhibitor Sales Quantity by Country (2020-2031)
8.3.2 Europe KRAS Inhibitor Consumption Value by Country (2020-2031)
8.3.3 Germany Market Size and Forecast (2020-2031)
8.3.4 France Market Size and Forecast (2020-2031)
8.3.5 United Kingdom Market Size and Forecast (2020-2031)
8.3.6 Russia Market Size and Forecast (2020-2031)
8.3.7 Italy Market Size and Forecast (2020-2031)
9 ASIA-PACIFIC
9.1 Asia-Pacific KRAS Inhibitor Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific KRAS Inhibitor Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific KRAS Inhibitor Market Size by Region
9.3.1 Asia-Pacific KRAS Inhibitor Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific KRAS Inhibitor Consumption Value by Region (2020-2031)
9.3.3 China Market Size and Forecast (2020-2031)
9.3.4 Japan Market Size and Forecast (2020-2031)
9.3.5 South Korea Market Size and Forecast (2020-2031)
9.3.6 India Market Size and Forecast (2020-2031)
9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
9.3.8 Australia Market Size and Forecast (2020-2031)
10 SOUTH AMERICA
10.1 South America KRAS Inhibitor Sales Quantity by Type (2020-2031)
10.2 South America KRAS Inhibitor Sales Quantity by Application (2020-2031)
10.3 South America KRAS Inhibitor Market Size by Country
10.3.1 South America KRAS Inhibitor Sales Quantity by Country (2020-2031)
10.3.2 South America KRAS Inhibitor Consumption Value by Country (2020-2031)
10.3.3 Brazil Market Size and Forecast (2020-2031)
10.3.4 Argentina Market Size and Forecast (2020-2031)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa KRAS Inhibitor Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa KRAS Inhibitor Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa KRAS Inhibitor Market Size by Country
11.3.1 Middle East & Africa KRAS Inhibitor Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa KRAS Inhibitor Consumption Value by Country (2020-2031)
11.3.3 Turkey Market Size and Forecast (2020-2031)
11.3.4 Egypt Market Size and Forecast (2020-2031)
11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
11.3.6 South Africa Market Size and Forecast (2020-2031)
12 MARKET DYNAMICS
12.1 KRAS Inhibitor Market Drivers
12.2 KRAS Inhibitor Market Restraints
12.3 KRAS Inhibitor Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of KRAS Inhibitor and Key Manufacturers
13.2 Manufacturing Costs Percentage of KRAS Inhibitor
13.3 KRAS Inhibitor Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 KRAS Inhibitor Typical Distributors
14.3 KRAS Inhibitor Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global KRAS Inhibitor Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Lung Cancer
1.3.3 Pancreatic Cancer
1.3.4 Colorectal Cancer
1.3.5 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global KRAS Inhibitor Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Clinic Laboratories
1.4.3 Cancer Diagnostic Centres
1.4.4 Hospitals
1.4.5 Others
1.5 Global KRAS Inhibitor Market Size & Forecast
1.5.1 Global KRAS Inhibitor Consumption Value (2020 & 2024 & 2031)
1.5.2 Global KRAS Inhibitor Sales Quantity (2020-2031)
1.5.3 Global KRAS Inhibitor Average Price (2020-2031)
2 MANUFACTURERS PROFILES
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen KRAS Inhibitor Product and Services
2.1.4 Amgen KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Amgen Recent Developments/Updates
2.2 Boehringer Ingelheim
2.2.1 Boehringer Ingelheim Details
2.2.2 Boehringer Ingelheim Major Business
2.2.3 Boehringer Ingelheim KRAS Inhibitor Product and Services
2.2.4 Boehringer Ingelheim KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Boehringer Ingelheim Recent Developments/Updates
2.3 BridgeBio Pharma
2.3.1 BridgeBio Pharma Details
2.3.2 BridgeBio Pharma Major Business
2.3.3 BridgeBio Pharma KRAS Inhibitor Product and Services
2.3.4 BridgeBio Pharma KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 BridgeBio Pharma Recent Developments/Updates
2.4 Erasca
2.4.1 Erasca Details
2.4.2 Erasca Major Business
2.4.3 Erasca KRAS Inhibitor Product and Services
2.4.4 Erasca KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Erasca Recent Developments/Updates
2.5 Innovent Biologics
2.5.1 Innovent Biologics Details
2.5.2 Innovent Biologics Major Business
2.5.3 Innovent Biologics KRAS Inhibitor Product and Services
2.5.4 Innovent Biologics KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Innovent Biologics Recent Developments/Updates
2.6 Incyte
2.6.1 Incyte Details
2.6.2 Incyte Major Business
2.6.3 Incyte KRAS Inhibitor Product and Services
2.6.4 Incyte KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Incyte Recent Developments/Updates
2.7 Mirati Therapeutics
2.7.1 Mirati Therapeutics Details
2.7.2 Mirati Therapeutics Major Business
2.7.3 Mirati Therapeutics KRAS Inhibitor Product and Services
2.7.4 Mirati Therapeutics KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Mirati Therapeutics Recent Developments/Updates
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis KRAS Inhibitor Product and Services
2.8.4 Novartis KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Novartis Recent Developments/Updates
2.9 Jemincare
2.9.1 Jemincare Details
2.9.2 Jemincare Major Business
2.9.3 Jemincare KRAS Inhibitor Product and Services
2.9.4 Jemincare KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Jemincare Recent Developments/Updates
2.10 Cardiff Oncology
2.10.1 Cardiff Oncology Details
2.10.2 Cardiff Oncology Major Business
2.10.3 Cardiff Oncology KRAS Inhibitor Product and Services
2.10.4 Cardiff Oncology KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Cardiff Oncology Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: KRAS INHIBITOR BY MANUFACTURER
3.1 Global KRAS Inhibitor Sales Quantity by Manufacturer (2020-2025)
3.2 Global KRAS Inhibitor Revenue by Manufacturer (2020-2025)
3.3 Global KRAS Inhibitor Average Price by Manufacturer (2020-2025)
3.4 Market Share Analysis (2024)
3.4.1 Producer Shipments of KRAS Inhibitor by Manufacturer Revenue ($MM) and Market Share (%): 2024
3.4.2 Top 3 KRAS Inhibitor Manufacturer Market Share in 2024
3.4.3 Top 6 KRAS Inhibitor Manufacturer Market Share in 2024
3.5 KRAS Inhibitor Market: Overall Company Footprint Analysis
3.5.1 KRAS Inhibitor Market: Region Footprint
3.5.2 KRAS Inhibitor Market: Company Product Type Footprint
3.5.3 KRAS Inhibitor Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global KRAS Inhibitor Market Size by Region
4.1.1 Global KRAS Inhibitor Sales Quantity by Region (2020-2031)
4.1.2 Global KRAS Inhibitor Consumption Value by Region (2020-2031)
4.1.3 Global KRAS Inhibitor Average Price by Region (2020-2031)
4.2 North America KRAS Inhibitor Consumption Value (2020-2031)
4.3 Europe KRAS Inhibitor Consumption Value (2020-2031)
4.4 Asia-Pacific KRAS Inhibitor Consumption Value (2020-2031)
4.5 South America KRAS Inhibitor Consumption Value (2020-2031)
4.6 Middle East & Africa KRAS Inhibitor Consumption Value (2020-2031)
5 MARKET SEGMENT BY TYPE
5.1 Global KRAS Inhibitor Sales Quantity by Type (2020-2031)
5.2 Global KRAS Inhibitor Consumption Value by Type (2020-2031)
5.3 Global KRAS Inhibitor Average Price by Type (2020-2031)
6 MARKET SEGMENT BY APPLICATION
6.1 Global KRAS Inhibitor Sales Quantity by Application (2020-2031)
6.2 Global KRAS Inhibitor Consumption Value by Application (2020-2031)
6.3 Global KRAS Inhibitor Average Price by Application (2020-2031)
7 NORTH AMERICA
7.1 North America KRAS Inhibitor Sales Quantity by Type (2020-2031)
7.2 North America KRAS Inhibitor Sales Quantity by Application (2020-2031)
7.3 North America KRAS Inhibitor Market Size by Country
7.3.1 North America KRAS Inhibitor Sales Quantity by Country (2020-2031)
7.3.2 North America KRAS Inhibitor Consumption Value by Country (2020-2031)
7.3.3 United States Market Size and Forecast (2020-2031)
7.3.4 Canada Market Size and Forecast (2020-2031)
7.3.5 Mexico Market Size and Forecast (2020-2031)
8 EUROPE
8.1 Europe KRAS Inhibitor Sales Quantity by Type (2020-2031)
8.2 Europe KRAS Inhibitor Sales Quantity by Application (2020-2031)
8.3 Europe KRAS Inhibitor Market Size by Country
8.3.1 Europe KRAS Inhibitor Sales Quantity by Country (2020-2031)
8.3.2 Europe KRAS Inhibitor Consumption Value by Country (2020-2031)
8.3.3 Germany Market Size and Forecast (2020-2031)
8.3.4 France Market Size and Forecast (2020-2031)
8.3.5 United Kingdom Market Size and Forecast (2020-2031)
8.3.6 Russia Market Size and Forecast (2020-2031)
8.3.7 Italy Market Size and Forecast (2020-2031)
9 ASIA-PACIFIC
9.1 Asia-Pacific KRAS Inhibitor Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific KRAS Inhibitor Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific KRAS Inhibitor Market Size by Region
9.3.1 Asia-Pacific KRAS Inhibitor Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific KRAS Inhibitor Consumption Value by Region (2020-2031)
9.3.3 China Market Size and Forecast (2020-2031)
9.3.4 Japan Market Size and Forecast (2020-2031)
9.3.5 South Korea Market Size and Forecast (2020-2031)
9.3.6 India Market Size and Forecast (2020-2031)
9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
9.3.8 Australia Market Size and Forecast (2020-2031)
10 SOUTH AMERICA
10.1 South America KRAS Inhibitor Sales Quantity by Type (2020-2031)
10.2 South America KRAS Inhibitor Sales Quantity by Application (2020-2031)
10.3 South America KRAS Inhibitor Market Size by Country
10.3.1 South America KRAS Inhibitor Sales Quantity by Country (2020-2031)
10.3.2 South America KRAS Inhibitor Consumption Value by Country (2020-2031)
10.3.3 Brazil Market Size and Forecast (2020-2031)
10.3.4 Argentina Market Size and Forecast (2020-2031)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa KRAS Inhibitor Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa KRAS Inhibitor Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa KRAS Inhibitor Market Size by Country
11.3.1 Middle East & Africa KRAS Inhibitor Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa KRAS Inhibitor Consumption Value by Country (2020-2031)
11.3.3 Turkey Market Size and Forecast (2020-2031)
11.3.4 Egypt Market Size and Forecast (2020-2031)
11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
11.3.6 South Africa Market Size and Forecast (2020-2031)
12 MARKET DYNAMICS
12.1 KRAS Inhibitor Market Drivers
12.2 KRAS Inhibitor Market Restraints
12.3 KRAS Inhibitor Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of KRAS Inhibitor and Key Manufacturers
13.2 Manufacturing Costs Percentage of KRAS Inhibitor
13.3 KRAS Inhibitor Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 KRAS Inhibitor Typical Distributors
14.3 KRAS Inhibitor Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global KRAS Inhibitor Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global KRAS Inhibitor Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Amgen Basic Information, Manufacturing Base and Competitors
Table 4. Amgen Major Business
Table 5. Amgen KRAS Inhibitor Product and Services
Table 6. Amgen KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 7. Amgen Recent Developments/Updates
Table 8. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 9. Boehringer Ingelheim Major Business
Table 10. Boehringer Ingelheim KRAS Inhibitor Product and Services
Table 11. Boehringer Ingelheim KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 12. Boehringer Ingelheim Recent Developments/Updates
Table 13. BridgeBio Pharma Basic Information, Manufacturing Base and Competitors
Table 14. BridgeBio Pharma Major Business
Table 15. BridgeBio Pharma KRAS Inhibitor Product and Services
Table 16. BridgeBio Pharma KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 17. BridgeBio Pharma Recent Developments/Updates
Table 18. Erasca Basic Information, Manufacturing Base and Competitors
Table 19. Erasca Major Business
Table 20. Erasca KRAS Inhibitor Product and Services
Table 21. Erasca KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 22. Erasca Recent Developments/Updates
Table 23. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 24. Innovent Biologics Major Business
Table 25. Innovent Biologics KRAS Inhibitor Product and Services
Table 26. Innovent Biologics KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 27. Innovent Biologics Recent Developments/Updates
Table 28. Incyte Basic Information, Manufacturing Base and Competitors
Table 29. Incyte Major Business
Table 30. Incyte KRAS Inhibitor Product and Services
Table 31. Incyte KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 32. Incyte Recent Developments/Updates
Table 33. Mirati Therapeutics Basic Information, Manufacturing Base and Competitors
Table 34. Mirati Therapeutics Major Business
Table 35. Mirati Therapeutics KRAS Inhibitor Product and Services
Table 36. Mirati Therapeutics KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 37. Mirati Therapeutics Recent Developments/Updates
Table 38. Novartis Basic Information, Manufacturing Base and Competitors
Table 39. Novartis Major Business
Table 40. Novartis KRAS Inhibitor Product and Services
Table 41. Novartis KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 42. Novartis Recent Developments/Updates
Table 43. Jemincare Basic Information, Manufacturing Base and Competitors
Table 44. Jemincare Major Business
Table 45. Jemincare KRAS Inhibitor Product and Services
Table 46. Jemincare KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 47. Jemincare Recent Developments/Updates
Table 48. Cardiff Oncology Basic Information, Manufacturing Base and Competitors
Table 49. Cardiff Oncology Major Business
Table 50. Cardiff Oncology KRAS Inhibitor Product and Services
Table 51. Cardiff Oncology KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 52. Cardiff Oncology Recent Developments/Updates
Table 53. Global KRAS Inhibitor Sales Quantity by Manufacturer (2020-2025) & (K Units)
Table 54. Global KRAS Inhibitor Revenue by Manufacturer (2020-2025) & (USD Million)
Table 55. Global KRAS Inhibitor Average Price by Manufacturer (2020-2025) & (US$/Unit)
Table 56. Market Position of Manufacturers in KRAS Inhibitor, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 57. Head Office and KRAS Inhibitor Production Site of Key Manufacturer
Table 58. KRAS Inhibitor Market: Company Product Type Footprint
Table 59. KRAS Inhibitor Market: Company Product Application Footprint
Table 60. KRAS Inhibitor New Market Entrants and Barriers to Market Entry
Table 61. KRAS Inhibitor Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global KRAS Inhibitor Consumption Value by Region (2020-2024-2031) & (USD Million) & CAGR
Table 63. Global KRAS Inhibitor Sales Quantity by Region (2020-2025) & (K Units)
Table 64. Global KRAS Inhibitor Sales Quantity by Region (2026-2031) & (K Units)
Table 65. Global KRAS Inhibitor Consumption Value by Region (2020-2025) & (USD Million)
Table 66. Global KRAS Inhibitor Consumption Value by Region (2026-2031) & (USD Million)
Table 67. Global KRAS Inhibitor Average Price by Region (2020-2025) & (US$/Unit)
Table 68. Global KRAS Inhibitor Average Price by Region (2026-2031) & (US$/Unit)
Table 69. Global KRAS Inhibitor Sales Quantity by Type (2020-2025) & (K Units)
Table 70. Global KRAS Inhibitor Sales Quantity by Type (2026-2031) & (K Units)
Table 71. Global KRAS Inhibitor Consumption Value by Type (2020-2025) & (USD Million)
Table 72. Global KRAS Inhibitor Consumption Value by Type (2026-2031) & (USD Million)
Table 73. Global KRAS Inhibitor Average Price by Type (2020-2025) & (US$/Unit)
Table 74. Global KRAS Inhibitor Average Price by Type (2026-2031) & (US$/Unit)
Table 75. Global KRAS Inhibitor Sales Quantity by Application (2020-2025) & (K Units)
Table 76. Global KRAS Inhibitor Sales Quantity by Application (2026-2031) & (K Units)
Table 77. Global KRAS Inhibitor Consumption Value by Application (2020-2025) & (USD Million)
Table 78. Global KRAS Inhibitor Consumption Value by Application (2026-2031) & (USD Million)
Table 79. Global KRAS Inhibitor Average Price by Application (2020-2025) & (US$/Unit)
Table 80. Global KRAS Inhibitor Average Price by Application (2026-2031) & (US$/Unit)
Table 81. North America KRAS Inhibitor Sales Quantity by Type (2020-2025) & (K Units)
Table 82. North America KRAS Inhibitor Sales Quantity by Type (2026-2031) & (K Units)
Table 83. North America KRAS Inhibitor Sales Quantity by Application (2020-2025) & (K Units)
Table 84. North America KRAS Inhibitor Sales Quantity by Application (2026-2031) & (K Units)
Table 85. North America KRAS Inhibitor Sales Quantity by Country (2020-2025) & (K Units)
Table 86. North America KRAS Inhibitor Sales Quantity by Country (2026-2031) & (K Units)
Table 87. North America KRAS Inhibitor Consumption Value by Country (2020-2025) & (USD Million)
Table 88. North America KRAS Inhibitor Consumption Value by Country (2026-2031) & (USD Million)
Table 89. Europe KRAS Inhibitor Sales Quantity by Type (2020-2025) & (K Units)
Table 90. Europe KRAS Inhibitor Sales Quantity by Type (2026-2031) & (K Units)
Table 91. Europe KRAS Inhibitor Sales Quantity by Application (2020-2025) & (K Units)
Table 92. Europe KRAS Inhibitor Sales Quantity by Application (2026-2031) & (K Units)
Table 93. Europe KRAS Inhibitor Sales Quantity by Country (2020-2025) & (K Units)
Table 94. Europe KRAS Inhibitor Sales Quantity by Country (2026-2031) & (K Units)
Table 95. Europe KRAS Inhibitor Consumption Value by Country (2020-2025) & (USD Million)
Table 96. Europe KRAS Inhibitor Consumption Value by Country (2026-2031) & (USD Million)
Table 97. Asia-Pacific KRAS Inhibitor Sales Quantity by Type (2020-2025) & (K Units)
Table 98. Asia-Pacific KRAS Inhibitor Sales Quantity by Type (2026-2031) & (K Units)
Table 99. Asia-Pacific KRAS Inhibitor Sales Quantity by Application (2020-2025) & (K Units)
Table 100. Asia-Pacific KRAS Inhibitor Sales Quantity by Application (2026-2031) & (K Units)
Table 101. Asia-Pacific KRAS Inhibitor Sales Quantity by Region (2020-2025) & (K Units)
Table 102. Asia-Pacific KRAS Inhibitor Sales Quantity by Region (2026-2031) & (K Units)
Table 103. Asia-Pacific KRAS Inhibitor Consumption Value by Region (2020-2025) & (USD Million)
Table 104. Asia-Pacific KRAS Inhibitor Consumption Value by Region (2026-2031) & (USD Million)
Table 105. South America KRAS Inhibitor Sales Quantity by Type (2020-2025) & (K Units)
Table 106. South America KRAS Inhibitor Sales Quantity by Type (2026-2031) & (K Units)
Table 107. South America KRAS Inhibitor Sales Quantity by Application (2020-2025) & (K Units)
Table 108. South America KRAS Inhibitor Sales Quantity by Application (2026-2031) & (K Units)
Table 109. South America KRAS Inhibitor Sales Quantity by Country (2020-2025) & (K Units)
Table 110. South America KRAS Inhibitor Sales Quantity by Country (2026-2031) & (K Units)
Table 111. South America KRAS Inhibitor Consumption Value by Country (2020-2025) & (USD Million)
Table 112. South America KRAS Inhibitor Consumption Value by Country (2026-2031) & (USD Million)
Table 113. Middle East & Africa KRAS Inhibitor Sales Quantity by Type (2020-2025) & (K Units)
Table 114. Middle East & Africa KRAS Inhibitor Sales Quantity by Type (2026-2031) & (K Units)
Table 115. Middle East & Africa KRAS Inhibitor Sales Quantity by Application (2020-2025) & (K Units)
Table 116. Middle East & Africa KRAS Inhibitor Sales Quantity by Application (2026-2031) & (K Units)
Table 117. Middle East & Africa KRAS Inhibitor Sales Quantity by Country (2020-2025) & (K Units)
Table 118. Middle East & Africa KRAS Inhibitor Sales Quantity by Country (2026-2031) & (K Units)
Table 119. Middle East & Africa KRAS Inhibitor Consumption Value by Country (2020-2025) & (USD Million)
Table 120. Middle East & Africa KRAS Inhibitor Consumption Value by Country (2026-2031) & (USD Million)
Table 121. KRAS Inhibitor Raw Material
Table 122. Key Manufacturers of KRAS Inhibitor Raw Materials
Table 123. KRAS Inhibitor Typical Distributors
Table 124. KRAS Inhibitor Typical Customers
Table 1. Global KRAS Inhibitor Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global KRAS Inhibitor Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Amgen Basic Information, Manufacturing Base and Competitors
Table 4. Amgen Major Business
Table 5. Amgen KRAS Inhibitor Product and Services
Table 6. Amgen KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 7. Amgen Recent Developments/Updates
Table 8. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 9. Boehringer Ingelheim Major Business
Table 10. Boehringer Ingelheim KRAS Inhibitor Product and Services
Table 11. Boehringer Ingelheim KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 12. Boehringer Ingelheim Recent Developments/Updates
Table 13. BridgeBio Pharma Basic Information, Manufacturing Base and Competitors
Table 14. BridgeBio Pharma Major Business
Table 15. BridgeBio Pharma KRAS Inhibitor Product and Services
Table 16. BridgeBio Pharma KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 17. BridgeBio Pharma Recent Developments/Updates
Table 18. Erasca Basic Information, Manufacturing Base and Competitors
Table 19. Erasca Major Business
Table 20. Erasca KRAS Inhibitor Product and Services
Table 21. Erasca KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 22. Erasca Recent Developments/Updates
Table 23. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 24. Innovent Biologics Major Business
Table 25. Innovent Biologics KRAS Inhibitor Product and Services
Table 26. Innovent Biologics KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 27. Innovent Biologics Recent Developments/Updates
Table 28. Incyte Basic Information, Manufacturing Base and Competitors
Table 29. Incyte Major Business
Table 30. Incyte KRAS Inhibitor Product and Services
Table 31. Incyte KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 32. Incyte Recent Developments/Updates
Table 33. Mirati Therapeutics Basic Information, Manufacturing Base and Competitors
Table 34. Mirati Therapeutics Major Business
Table 35. Mirati Therapeutics KRAS Inhibitor Product and Services
Table 36. Mirati Therapeutics KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 37. Mirati Therapeutics Recent Developments/Updates
Table 38. Novartis Basic Information, Manufacturing Base and Competitors
Table 39. Novartis Major Business
Table 40. Novartis KRAS Inhibitor Product and Services
Table 41. Novartis KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 42. Novartis Recent Developments/Updates
Table 43. Jemincare Basic Information, Manufacturing Base and Competitors
Table 44. Jemincare Major Business
Table 45. Jemincare KRAS Inhibitor Product and Services
Table 46. Jemincare KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 47. Jemincare Recent Developments/Updates
Table 48. Cardiff Oncology Basic Information, Manufacturing Base and Competitors
Table 49. Cardiff Oncology Major Business
Table 50. Cardiff Oncology KRAS Inhibitor Product and Services
Table 51. Cardiff Oncology KRAS Inhibitor Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 52. Cardiff Oncology Recent Developments/Updates
Table 53. Global KRAS Inhibitor Sales Quantity by Manufacturer (2020-2025) & (K Units)
Table 54. Global KRAS Inhibitor Revenue by Manufacturer (2020-2025) & (USD Million)
Table 55. Global KRAS Inhibitor Average Price by Manufacturer (2020-2025) & (US$/Unit)
Table 56. Market Position of Manufacturers in KRAS Inhibitor, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 57. Head Office and KRAS Inhibitor Production Site of Key Manufacturer
Table 58. KRAS Inhibitor Market: Company Product Type Footprint
Table 59. KRAS Inhibitor Market: Company Product Application Footprint
Table 60. KRAS Inhibitor New Market Entrants and Barriers to Market Entry
Table 61. KRAS Inhibitor Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global KRAS Inhibitor Consumption Value by Region (2020-2024-2031) & (USD Million) & CAGR
Table 63. Global KRAS Inhibitor Sales Quantity by Region (2020-2025) & (K Units)
Table 64. Global KRAS Inhibitor Sales Quantity by Region (2026-2031) & (K Units)
Table 65. Global KRAS Inhibitor Consumption Value by Region (2020-2025) & (USD Million)
Table 66. Global KRAS Inhibitor Consumption Value by Region (2026-2031) & (USD Million)
Table 67. Global KRAS Inhibitor Average Price by Region (2020-2025) & (US$/Unit)
Table 68. Global KRAS Inhibitor Average Price by Region (2026-2031) & (US$/Unit)
Table 69. Global KRAS Inhibitor Sales Quantity by Type (2020-2025) & (K Units)
Table 70. Global KRAS Inhibitor Sales Quantity by Type (2026-2031) & (K Units)
Table 71. Global KRAS Inhibitor Consumption Value by Type (2020-2025) & (USD Million)
Table 72. Global KRAS Inhibitor Consumption Value by Type (2026-2031) & (USD Million)
Table 73. Global KRAS Inhibitor Average Price by Type (2020-2025) & (US$/Unit)
Table 74. Global KRAS Inhibitor Average Price by Type (2026-2031) & (US$/Unit)
Table 75. Global KRAS Inhibitor Sales Quantity by Application (2020-2025) & (K Units)
Table 76. Global KRAS Inhibitor Sales Quantity by Application (2026-2031) & (K Units)
Table 77. Global KRAS Inhibitor Consumption Value by Application (2020-2025) & (USD Million)
Table 78. Global KRAS Inhibitor Consumption Value by Application (2026-2031) & (USD Million)
Table 79. Global KRAS Inhibitor Average Price by Application (2020-2025) & (US$/Unit)
Table 80. Global KRAS Inhibitor Average Price by Application (2026-2031) & (US$/Unit)
Table 81. North America KRAS Inhibitor Sales Quantity by Type (2020-2025) & (K Units)
Table 82. North America KRAS Inhibitor Sales Quantity by Type (2026-2031) & (K Units)
Table 83. North America KRAS Inhibitor Sales Quantity by Application (2020-2025) & (K Units)
Table 84. North America KRAS Inhibitor Sales Quantity by Application (2026-2031) & (K Units)
Table 85. North America KRAS Inhibitor Sales Quantity by Country (2020-2025) & (K Units)
Table 86. North America KRAS Inhibitor Sales Quantity by Country (2026-2031) & (K Units)
Table 87. North America KRAS Inhibitor Consumption Value by Country (2020-2025) & (USD Million)
Table 88. North America KRAS Inhibitor Consumption Value by Country (2026-2031) & (USD Million)
Table 89. Europe KRAS Inhibitor Sales Quantity by Type (2020-2025) & (K Units)
Table 90. Europe KRAS Inhibitor Sales Quantity by Type (2026-2031) & (K Units)
Table 91. Europe KRAS Inhibitor Sales Quantity by Application (2020-2025) & (K Units)
Table 92. Europe KRAS Inhibitor Sales Quantity by Application (2026-2031) & (K Units)
Table 93. Europe KRAS Inhibitor Sales Quantity by Country (2020-2025) & (K Units)
Table 94. Europe KRAS Inhibitor Sales Quantity by Country (2026-2031) & (K Units)
Table 95. Europe KRAS Inhibitor Consumption Value by Country (2020-2025) & (USD Million)
Table 96. Europe KRAS Inhibitor Consumption Value by Country (2026-2031) & (USD Million)
Table 97. Asia-Pacific KRAS Inhibitor Sales Quantity by Type (2020-2025) & (K Units)
Table 98. Asia-Pacific KRAS Inhibitor Sales Quantity by Type (2026-2031) & (K Units)
Table 99. Asia-Pacific KRAS Inhibitor Sales Quantity by Application (2020-2025) & (K Units)
Table 100. Asia-Pacific KRAS Inhibitor Sales Quantity by Application (2026-2031) & (K Units)
Table 101. Asia-Pacific KRAS Inhibitor Sales Quantity by Region (2020-2025) & (K Units)
Table 102. Asia-Pacific KRAS Inhibitor Sales Quantity by Region (2026-2031) & (K Units)
Table 103. Asia-Pacific KRAS Inhibitor Consumption Value by Region (2020-2025) & (USD Million)
Table 104. Asia-Pacific KRAS Inhibitor Consumption Value by Region (2026-2031) & (USD Million)
Table 105. South America KRAS Inhibitor Sales Quantity by Type (2020-2025) & (K Units)
Table 106. South America KRAS Inhibitor Sales Quantity by Type (2026-2031) & (K Units)
Table 107. South America KRAS Inhibitor Sales Quantity by Application (2020-2025) & (K Units)
Table 108. South America KRAS Inhibitor Sales Quantity by Application (2026-2031) & (K Units)
Table 109. South America KRAS Inhibitor Sales Quantity by Country (2020-2025) & (K Units)
Table 110. South America KRAS Inhibitor Sales Quantity by Country (2026-2031) & (K Units)
Table 111. South America KRAS Inhibitor Consumption Value by Country (2020-2025) & (USD Million)
Table 112. South America KRAS Inhibitor Consumption Value by Country (2026-2031) & (USD Million)
Table 113. Middle East & Africa KRAS Inhibitor Sales Quantity by Type (2020-2025) & (K Units)
Table 114. Middle East & Africa KRAS Inhibitor Sales Quantity by Type (2026-2031) & (K Units)
Table 115. Middle East & Africa KRAS Inhibitor Sales Quantity by Application (2020-2025) & (K Units)
Table 116. Middle East & Africa KRAS Inhibitor Sales Quantity by Application (2026-2031) & (K Units)
Table 117. Middle East & Africa KRAS Inhibitor Sales Quantity by Country (2020-2025) & (K Units)
Table 118. Middle East & Africa KRAS Inhibitor Sales Quantity by Country (2026-2031) & (K Units)
Table 119. Middle East & Africa KRAS Inhibitor Consumption Value by Country (2020-2025) & (USD Million)
Table 120. Middle East & Africa KRAS Inhibitor Consumption Value by Country (2026-2031) & (USD Million)
Table 121. KRAS Inhibitor Raw Material
Table 122. Key Manufacturers of KRAS Inhibitor Raw Materials
Table 123. KRAS Inhibitor Typical Distributors
Table 124. KRAS Inhibitor Typical Customers
LIST OF FIGURES
Figure 1. KRAS Inhibitor Picture
Figure 2. Global KRAS Inhibitor Revenue by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global KRAS Inhibitor Revenue Market Share by Type in 2024
Figure 4. Lung Cancer Examples
Figure 5. Pancreatic Cancer Examples
Figure 6. Colorectal Cancer Examples
Figure 7. Others Examples
Figure 8. Global KRAS Inhibitor Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 9. Global KRAS Inhibitor Revenue Market Share by Application in 2024
Figure 10. Clinic Laboratories Examples
Figure 11. Cancer Diagnostic Centres Examples
Figure 12. Hospitals Examples
Figure 13. Others Examples
Figure 14. Global KRAS Inhibitor Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 15. Global KRAS Inhibitor Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 16. Global KRAS Inhibitor Sales Quantity (2020-2031) & (K Units)
Figure 17. Global KRAS Inhibitor Price (2020-2031) & (US$/Unit)
Figure 18. Global KRAS Inhibitor Sales Quantity Market Share by Manufacturer in 2024
Figure 19. Global KRAS Inhibitor Revenue Market Share by Manufacturer in 2024
Figure 20. Producer Shipments of KRAS Inhibitor by Manufacturer Sales ($MM) and Market Share (%): 2024
Figure 21. Top 3 KRAS Inhibitor Manufacturer (Revenue) Market Share in 2024
Figure 22. Top 6 KRAS Inhibitor Manufacturer (Revenue) Market Share in 2024
Figure 23. Global KRAS Inhibitor Sales Quantity Market Share by Region (2020-2031)
Figure 24. Global KRAS Inhibitor Consumption Value Market Share by Region (2020-2031)
Figure 25. North America KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 26. Europe KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 27. Asia-Pacific KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 28. South America KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 29. Middle East & Africa KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 30. Global KRAS Inhibitor Sales Quantity Market Share by Type (2020-2031)
Figure 31. Global KRAS Inhibitor Consumption Value Market Share by Type (2020-2031)
Figure 32. Global KRAS Inhibitor Average Price by Type (2020-2031) & (US$/Unit)
Figure 33. Global KRAS Inhibitor Sales Quantity Market Share by Application (2020-2031)
Figure 34. Global KRAS Inhibitor Revenue Market Share by Application (2020-2031)
Figure 35. Global KRAS Inhibitor Average Price by Application (2020-2031) & (US$/Unit)
Figure 36. North America KRAS Inhibitor Sales Quantity Market Share by Type (2020-2031)
Figure 37. North America KRAS Inhibitor Sales Quantity Market Share by Application (2020-2031)
Figure 38. North America KRAS Inhibitor Sales Quantity Market Share by Country (2020-2031)
Figure 39. North America KRAS Inhibitor Consumption Value Market Share by Country (2020-2031)
Figure 40. United States KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 41. Canada KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 42. Mexico KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 43. Europe KRAS Inhibitor Sales Quantity Market Share by Type (2020-2031)
Figure 44. Europe KRAS Inhibitor Sales Quantity Market Share by Application (2020-2031)
Figure 45. Europe KRAS Inhibitor Sales Quantity Market Share by Country (2020-2031)
Figure 46. Europe KRAS Inhibitor Consumption Value Market Share by Country (2020-2031)
Figure 47. Germany KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 48. France KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 49. United Kingdom KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 50. Russia KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 51. Italy KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 52. Asia-Pacific KRAS Inhibitor Sales Quantity Market Share by Type (2020-2031)
Figure 53. Asia-Pacific KRAS Inhibitor Sales Quantity Market Share by Application (2020-2031)
Figure 54. Asia-Pacific KRAS Inhibitor Sales Quantity Market Share by Region (2020-2031)
Figure 55. Asia-Pacific KRAS Inhibitor Consumption Value Market Share by Region (2020-2031)
Figure 56. China KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 57. Japan KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 58. South Korea KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 59. India KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 60. Southeast Asia KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 61. Australia KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 62. South America KRAS Inhibitor Sales Quantity Market Share by Type (2020-2031)
Figure 63. South America KRAS Inhibitor Sales Quantity Market Share by Application (2020-2031)
Figure 64. South America KRAS Inhibitor Sales Quantity Market Share by Country (2020-2031)
Figure 65. South America KRAS Inhibitor Consumption Value Market Share by Country (2020-2031)
Figure 66. Brazil KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 67. Argentina KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 68. Middle East & Africa KRAS Inhibitor Sales Quantity Market Share by Type (2020-2031)
Figure 69. Middle East & Africa KRAS Inhibitor Sales Quantity Market Share by Application (2020-2031)
Figure 70. Middle East & Africa KRAS Inhibitor Sales Quantity Market Share by Country (2020-2031)
Figure 71. Middle East & Africa KRAS Inhibitor Consumption Value Market Share by Country (2020-2031)
Figure 72. Turkey KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 73. Egypt KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 74. Saudi Arabia KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 75. South Africa KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 76. KRAS Inhibitor Market Drivers
Figure 77. KRAS Inhibitor Market Restraints
Figure 78. KRAS Inhibitor Market Trends
Figure 79. Porters Five Forces Analysis
Figure 80. Manufacturing Cost Structure Analysis of KRAS Inhibitor in 2024
Figure 81. Manufacturing Process Analysis of KRAS Inhibitor
Figure 82. KRAS Inhibitor Industrial Chain
Figure 83. Sales Channel: Direct to End-User vs Distributors
Figure 84. Direct Channel Pros & Cons
Figure 85. Indirect Channel Pros & Cons
Figure 86. Methodology
Figure 87. Research Process and Data Source
Figure 1. KRAS Inhibitor Picture
Figure 2. Global KRAS Inhibitor Revenue by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global KRAS Inhibitor Revenue Market Share by Type in 2024
Figure 4. Lung Cancer Examples
Figure 5. Pancreatic Cancer Examples
Figure 6. Colorectal Cancer Examples
Figure 7. Others Examples
Figure 8. Global KRAS Inhibitor Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 9. Global KRAS Inhibitor Revenue Market Share by Application in 2024
Figure 10. Clinic Laboratories Examples
Figure 11. Cancer Diagnostic Centres Examples
Figure 12. Hospitals Examples
Figure 13. Others Examples
Figure 14. Global KRAS Inhibitor Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 15. Global KRAS Inhibitor Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 16. Global KRAS Inhibitor Sales Quantity (2020-2031) & (K Units)
Figure 17. Global KRAS Inhibitor Price (2020-2031) & (US$/Unit)
Figure 18. Global KRAS Inhibitor Sales Quantity Market Share by Manufacturer in 2024
Figure 19. Global KRAS Inhibitor Revenue Market Share by Manufacturer in 2024
Figure 20. Producer Shipments of KRAS Inhibitor by Manufacturer Sales ($MM) and Market Share (%): 2024
Figure 21. Top 3 KRAS Inhibitor Manufacturer (Revenue) Market Share in 2024
Figure 22. Top 6 KRAS Inhibitor Manufacturer (Revenue) Market Share in 2024
Figure 23. Global KRAS Inhibitor Sales Quantity Market Share by Region (2020-2031)
Figure 24. Global KRAS Inhibitor Consumption Value Market Share by Region (2020-2031)
Figure 25. North America KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 26. Europe KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 27. Asia-Pacific KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 28. South America KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 29. Middle East & Africa KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 30. Global KRAS Inhibitor Sales Quantity Market Share by Type (2020-2031)
Figure 31. Global KRAS Inhibitor Consumption Value Market Share by Type (2020-2031)
Figure 32. Global KRAS Inhibitor Average Price by Type (2020-2031) & (US$/Unit)
Figure 33. Global KRAS Inhibitor Sales Quantity Market Share by Application (2020-2031)
Figure 34. Global KRAS Inhibitor Revenue Market Share by Application (2020-2031)
Figure 35. Global KRAS Inhibitor Average Price by Application (2020-2031) & (US$/Unit)
Figure 36. North America KRAS Inhibitor Sales Quantity Market Share by Type (2020-2031)
Figure 37. North America KRAS Inhibitor Sales Quantity Market Share by Application (2020-2031)
Figure 38. North America KRAS Inhibitor Sales Quantity Market Share by Country (2020-2031)
Figure 39. North America KRAS Inhibitor Consumption Value Market Share by Country (2020-2031)
Figure 40. United States KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 41. Canada KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 42. Mexico KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 43. Europe KRAS Inhibitor Sales Quantity Market Share by Type (2020-2031)
Figure 44. Europe KRAS Inhibitor Sales Quantity Market Share by Application (2020-2031)
Figure 45. Europe KRAS Inhibitor Sales Quantity Market Share by Country (2020-2031)
Figure 46. Europe KRAS Inhibitor Consumption Value Market Share by Country (2020-2031)
Figure 47. Germany KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 48. France KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 49. United Kingdom KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 50. Russia KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 51. Italy KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 52. Asia-Pacific KRAS Inhibitor Sales Quantity Market Share by Type (2020-2031)
Figure 53. Asia-Pacific KRAS Inhibitor Sales Quantity Market Share by Application (2020-2031)
Figure 54. Asia-Pacific KRAS Inhibitor Sales Quantity Market Share by Region (2020-2031)
Figure 55. Asia-Pacific KRAS Inhibitor Consumption Value Market Share by Region (2020-2031)
Figure 56. China KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 57. Japan KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 58. South Korea KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 59. India KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 60. Southeast Asia KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 61. Australia KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 62. South America KRAS Inhibitor Sales Quantity Market Share by Type (2020-2031)
Figure 63. South America KRAS Inhibitor Sales Quantity Market Share by Application (2020-2031)
Figure 64. South America KRAS Inhibitor Sales Quantity Market Share by Country (2020-2031)
Figure 65. South America KRAS Inhibitor Consumption Value Market Share by Country (2020-2031)
Figure 66. Brazil KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 67. Argentina KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 68. Middle East & Africa KRAS Inhibitor Sales Quantity Market Share by Type (2020-2031)
Figure 69. Middle East & Africa KRAS Inhibitor Sales Quantity Market Share by Application (2020-2031)
Figure 70. Middle East & Africa KRAS Inhibitor Sales Quantity Market Share by Country (2020-2031)
Figure 71. Middle East & Africa KRAS Inhibitor Consumption Value Market Share by Country (2020-2031)
Figure 72. Turkey KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 73. Egypt KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 74. Saudi Arabia KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 75. South Africa KRAS Inhibitor Consumption Value (2020-2031) & (USD Million)
Figure 76. KRAS Inhibitor Market Drivers
Figure 77. KRAS Inhibitor Market Restraints
Figure 78. KRAS Inhibitor Market Trends
Figure 79. Porters Five Forces Analysis
Figure 80. Manufacturing Cost Structure Analysis of KRAS Inhibitor in 2024
Figure 81. Manufacturing Process Analysis of KRAS Inhibitor
Figure 82. KRAS Inhibitor Industrial Chain
Figure 83. Sales Channel: Direct to End-User vs Distributors
Figure 84. Direct Channel Pros & Cons
Figure 85. Indirect Channel Pros & Cons
Figure 86. Methodology
Figure 87. Research Process and Data Source
